Amlodipine in chronic stable angina: Results of a multicenter double-blind crossover trial

Michael D. Ezekowitz, Kenneth Hossack, Jawahar L. Mehta, Udho Thadani, Donald J. Weidler, William Kostuk, Najam Awan, William Grossman, William J Bommer

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The efficacy and safety of amiodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study. The trial consisted of an initial 2-week single-blind placebo period followed by a first period of 4 weeks at double-blind therapy, which was followed by a 1 week washout perioid and then a second 4-week double-blind period after treatments were crossed over. Twenty-four-hour Holter electrocardiographic monitoring was carried out in 12 patients at three centers. In the first double-blind period amiodipine prodcued a significantly greater increase in symptom-limited exercise duration (amiodipine 478.5 to 520.6 vs placebo 484.6 to 485.2 seconds; change +8.8% vs +0.1%, respectively; p = 0.0004) and total work (amiodipine 2426 to 2984 vs placebo 2505 to 2548 kilopondmeters; change +24% vs +1.7%, respectively; p = 0.0006) and a decrease in angina attack frequency (from 3 to 1 per week; p = 0.016) and nitroglycerin consumption (from 2 to 0.5 tablets/wk; p = 0.01) compared with placebo. Holter monitoring revealed significant reductions in numbers (amiodipine 4.65 to 2.22 vs placebo 1.84 to 1.54; change +52% vs +84%, respectively; p = 0.06), absolute total area (amiodipine 87.66 to 11.43 vs placebo 5.76 to 35.24; change +87% vs +513%, respectively; p = 0.02), and duration (amiodipine 12.29 to 2.95 vs 1.66 to 7.74 seconds; change +76% vs +367%, respectively; p = 0.008) of ST-segment depressions after treatment with amiodipine compared with placebo. After the treatments were crossed over changes continued to favor amiodipine. However, there were no significant changes by Holter monitoring in any of the ST-segment parameters during the period after the crossover. The smaller changes with amiodipine during the period after the crossover may be the result of the long half-life of amiodipine or an exercise training effect. The most frequently reported side effects with amiodipine were headache (11%) and edema (8%). We conclude that amiodipine therapy is well tolerated and that it demonstrates antiischemic and antianginal efficacy in the management of stable angina.

Original languageEnglish (US)
Pages (from-to)527-535
Number of pages9
JournalAmerican Heart Journal
Volume129
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Amlodipine
Stable Angina
Cross-Over Studies
Placebos
Ambulatory Electrocardiography
Exercise
Therapeutics
Nitroglycerin
Double-Blind Method
Tablets
Headache
Half-Life
Edema
Calcium
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Amlodipine in chronic stable angina : Results of a multicenter double-blind crossover trial. / Ezekowitz, Michael D.; Hossack, Kenneth; Mehta, Jawahar L.; Thadani, Udho; Weidler, Donald J.; Kostuk, William; Awan, Najam; Grossman, William; Bommer, William J.

In: American Heart Journal, Vol. 129, No. 3, 1995, p. 527-535.

Research output: Contribution to journalArticle

Ezekowitz, MD, Hossack, K, Mehta, JL, Thadani, U, Weidler, DJ, Kostuk, W, Awan, N, Grossman, W & Bommer, WJ 1995, 'Amlodipine in chronic stable angina: Results of a multicenter double-blind crossover trial', American Heart Journal, vol. 129, no. 3, pp. 527-535. https://doi.org/10.1016/0002-8703(95)90281-3
Ezekowitz, Michael D. ; Hossack, Kenneth ; Mehta, Jawahar L. ; Thadani, Udho ; Weidler, Donald J. ; Kostuk, William ; Awan, Najam ; Grossman, William ; Bommer, William J. / Amlodipine in chronic stable angina : Results of a multicenter double-blind crossover trial. In: American Heart Journal. 1995 ; Vol. 129, No. 3. pp. 527-535.
@article{af3b30b3314644a8a4f2886a00c6a65d,
title = "Amlodipine in chronic stable angina: Results of a multicenter double-blind crossover trial",
abstract = "The efficacy and safety of amiodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study. The trial consisted of an initial 2-week single-blind placebo period followed by a first period of 4 weeks at double-blind therapy, which was followed by a 1 week washout perioid and then a second 4-week double-blind period after treatments were crossed over. Twenty-four-hour Holter electrocardiographic monitoring was carried out in 12 patients at three centers. In the first double-blind period amiodipine prodcued a significantly greater increase in symptom-limited exercise duration (amiodipine 478.5 to 520.6 vs placebo 484.6 to 485.2 seconds; change +8.8{\%} vs +0.1{\%}, respectively; p = 0.0004) and total work (amiodipine 2426 to 2984 vs placebo 2505 to 2548 kilopondmeters; change +24{\%} vs +1.7{\%}, respectively; p = 0.0006) and a decrease in angina attack frequency (from 3 to 1 per week; p = 0.016) and nitroglycerin consumption (from 2 to 0.5 tablets/wk; p = 0.01) compared with placebo. Holter monitoring revealed significant reductions in numbers (amiodipine 4.65 to 2.22 vs placebo 1.84 to 1.54; change +52{\%} vs +84{\%}, respectively; p = 0.06), absolute total area (amiodipine 87.66 to 11.43 vs placebo 5.76 to 35.24; change +87{\%} vs +513{\%}, respectively; p = 0.02), and duration (amiodipine 12.29 to 2.95 vs 1.66 to 7.74 seconds; change +76{\%} vs +367{\%}, respectively; p = 0.008) of ST-segment depressions after treatment with amiodipine compared with placebo. After the treatments were crossed over changes continued to favor amiodipine. However, there were no significant changes by Holter monitoring in any of the ST-segment parameters during the period after the crossover. The smaller changes with amiodipine during the period after the crossover may be the result of the long half-life of amiodipine or an exercise training effect. The most frequently reported side effects with amiodipine were headache (11{\%}) and edema (8{\%}). We conclude that amiodipine therapy is well tolerated and that it demonstrates antiischemic and antianginal efficacy in the management of stable angina.",
author = "Ezekowitz, {Michael D.} and Kenneth Hossack and Mehta, {Jawahar L.} and Udho Thadani and Weidler, {Donald J.} and William Kostuk and Najam Awan and William Grossman and Bommer, {William J}",
year = "1995",
doi = "10.1016/0002-8703(95)90281-3",
language = "English (US)",
volume = "129",
pages = "527--535",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Amlodipine in chronic stable angina

T2 - Results of a multicenter double-blind crossover trial

AU - Ezekowitz, Michael D.

AU - Hossack, Kenneth

AU - Mehta, Jawahar L.

AU - Thadani, Udho

AU - Weidler, Donald J.

AU - Kostuk, William

AU - Awan, Najam

AU - Grossman, William

AU - Bommer, William J

PY - 1995

Y1 - 1995

N2 - The efficacy and safety of amiodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study. The trial consisted of an initial 2-week single-blind placebo period followed by a first period of 4 weeks at double-blind therapy, which was followed by a 1 week washout perioid and then a second 4-week double-blind period after treatments were crossed over. Twenty-four-hour Holter electrocardiographic monitoring was carried out in 12 patients at three centers. In the first double-blind period amiodipine prodcued a significantly greater increase in symptom-limited exercise duration (amiodipine 478.5 to 520.6 vs placebo 484.6 to 485.2 seconds; change +8.8% vs +0.1%, respectively; p = 0.0004) and total work (amiodipine 2426 to 2984 vs placebo 2505 to 2548 kilopondmeters; change +24% vs +1.7%, respectively; p = 0.0006) and a decrease in angina attack frequency (from 3 to 1 per week; p = 0.016) and nitroglycerin consumption (from 2 to 0.5 tablets/wk; p = 0.01) compared with placebo. Holter monitoring revealed significant reductions in numbers (amiodipine 4.65 to 2.22 vs placebo 1.84 to 1.54; change +52% vs +84%, respectively; p = 0.06), absolute total area (amiodipine 87.66 to 11.43 vs placebo 5.76 to 35.24; change +87% vs +513%, respectively; p = 0.02), and duration (amiodipine 12.29 to 2.95 vs 1.66 to 7.74 seconds; change +76% vs +367%, respectively; p = 0.008) of ST-segment depressions after treatment with amiodipine compared with placebo. After the treatments were crossed over changes continued to favor amiodipine. However, there were no significant changes by Holter monitoring in any of the ST-segment parameters during the period after the crossover. The smaller changes with amiodipine during the period after the crossover may be the result of the long half-life of amiodipine or an exercise training effect. The most frequently reported side effects with amiodipine were headache (11%) and edema (8%). We conclude that amiodipine therapy is well tolerated and that it demonstrates antiischemic and antianginal efficacy in the management of stable angina.

AB - The efficacy and safety of amiodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study. The trial consisted of an initial 2-week single-blind placebo period followed by a first period of 4 weeks at double-blind therapy, which was followed by a 1 week washout perioid and then a second 4-week double-blind period after treatments were crossed over. Twenty-four-hour Holter electrocardiographic monitoring was carried out in 12 patients at three centers. In the first double-blind period amiodipine prodcued a significantly greater increase in symptom-limited exercise duration (amiodipine 478.5 to 520.6 vs placebo 484.6 to 485.2 seconds; change +8.8% vs +0.1%, respectively; p = 0.0004) and total work (amiodipine 2426 to 2984 vs placebo 2505 to 2548 kilopondmeters; change +24% vs +1.7%, respectively; p = 0.0006) and a decrease in angina attack frequency (from 3 to 1 per week; p = 0.016) and nitroglycerin consumption (from 2 to 0.5 tablets/wk; p = 0.01) compared with placebo. Holter monitoring revealed significant reductions in numbers (amiodipine 4.65 to 2.22 vs placebo 1.84 to 1.54; change +52% vs +84%, respectively; p = 0.06), absolute total area (amiodipine 87.66 to 11.43 vs placebo 5.76 to 35.24; change +87% vs +513%, respectively; p = 0.02), and duration (amiodipine 12.29 to 2.95 vs 1.66 to 7.74 seconds; change +76% vs +367%, respectively; p = 0.008) of ST-segment depressions after treatment with amiodipine compared with placebo. After the treatments were crossed over changes continued to favor amiodipine. However, there were no significant changes by Holter monitoring in any of the ST-segment parameters during the period after the crossover. The smaller changes with amiodipine during the period after the crossover may be the result of the long half-life of amiodipine or an exercise training effect. The most frequently reported side effects with amiodipine were headache (11%) and edema (8%). We conclude that amiodipine therapy is well tolerated and that it demonstrates antiischemic and antianginal efficacy in the management of stable angina.

UR - http://www.scopus.com/inward/record.url?scp=0028968795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028968795&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(95)90281-3

DO - 10.1016/0002-8703(95)90281-3

M3 - Article

C2 - 7872184

AN - SCOPUS:0028968795

VL - 129

SP - 527

EP - 535

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -